Genomics and dementia — new drug targets ahead?
Pharmacogenetics — the application of genomic technologies such as gene sequencing and gene expression analysis to drugs — is beginning to make its impact on central nervous system drug development. The mapping of genes (including their polymorphisms) and their expression in normal and disease states to discover new drug targets will also change the scenery of dementia therapeutics’ development completely because it uses a “bottom-up” strategy, identifying genes whose expression is changed in dementia or by drug therapy. Drugs identified this way should be mechanistically novel, more potent and specific, and probably quicker to develop. Pharmaco-genomics can however also greatly contribute to the improvement of drugs targeting currently known receptors and enzymes.
KeywordsAlzheimer Disease Vascular Dementia Estrogen Receptor Alpha Gene Glutamate Transporter GLAST Estrogen Receptor Gene Polymorphism
Unable to display preview. Download preview PDF.
- Alvarez-Arcaya A, Combarros O, Llorca J, Sanchez-Guerra M, Berciano J, Fernandez-Luna JL (2001) The ¡ª 491 TT apolipoprotein E promoter polymorphism is associated with reduced risk for sporadic Alzheimer’s disease. Neurosci Lett 304: 204–208Google Scholar
- Bertram L, Guenette S, Jones J, Keeney D, Mullin K, Crystal A, Basu S, Yhu S, Deng A, Rebeck GW, Hyman BT, Go R, Mclnnis M, Blacker D, Tanzi R (2001) No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease. Ann Neurol 49: 114–116PubMedCrossRefGoogle Scholar
- Brandi ML, Becherini L, Gennari L, Racchi M, Bianchetti A, Nacmias B, Sorbi S, Mecocci P, Senin U, Govoni S (1999) Association of the estrogen receptor alpha geneGoogle Scholar
- polymorphisms with sporadic Alzheimer’s disease. Biochem Biophys Res Commun 265: 335–338Google Scholar
- Hawkins JW, Artinger M, Quigley ME (2001) Genomics and drug development: impacts and strategic implications. Decision Resources, Waltham, Mass, USA, pp 39–42Google Scholar
- Kovacs DM (2000) alpha2-macroglobulin in late-onset Alzheimer’s disease. Exp Gerontol 35: 473–479Google Scholar
- McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC, Mcllroy SP, Passmore AP (2001) Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer’s disease and vascular dementia: a case-control study. Lancet 357: 436–439PubMedCrossRefGoogle Scholar
- Song YQ, Rogaeva E, Premkumar S, Brindle N, Kawarai T, Orlacchio A, Yu G, Levesque G, Nishimura M, Ikeda M, Pei Y, O’Toole C, Duara R, Barker W, Sorbi S, Freedman M, Farrer L, St. George-Hyslop P (1998) Absence of association betweenAlzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett 250: 189–192CrossRefGoogle Scholar